Hard Brexit: MHRA Preparations
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
Register now for ECA's GMP Newsletter
Boris Johnson's election as Prime Minister has made it very likely that the UK will leave the EU on 31 October this year. And the likelihood of a withdrawal without an agreement ("Hard Brexit ") can no longer be dismissed. Pharmaceutical authorities see challenges for pharmaceutical manufacturers in many areas, not only in terms of drug availability or drug testing.
The MHRA has already published several guidelines for a possible no-deal scenario. This concerns the following areas:
- Medical Devices
- Clinical Trials
- Biologicals and ATMPs
- List if approved countries
- Trading in drug precursors
- QPPV and PV Master File
A comprehensive overview can be found in the Collection "MHRA guidance and publications about a possible no-deal Brexit".
Related GMP News
16.01.20252nd Version of the Union list of Critical Medicines published
16.01.2025Securing Europe's Drug Supply: How EDSForm is Addressing Medicine Shortages
15.01.2025FDA proposes Standardized Testing for Asbestos in Talc-Containing Cosmetic Products
18.12.2024What are the GMP Requirements for Consultants?
18.12.2024ICH published updated Q8/Q9/Q10 Questions & Answers Document
11.12.2024European Shortages Monitoring Platform (ESMP) has gone live